NCT03471260 2026-03-11Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer CenterPhase 1/2 Recruiting96 enrolled
NCT04774393 2025-11-10Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 1/2 Recruiting84 enrolled